Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
NicOx Announces Results for TPI 1020 in COPD
January 9th, 2009
NicOx S.A. (NYSE Euronext Paris: COX) announced the results of a phase 2a study for TPI 1020, conducted in 62 patients with Chronic Obstructive Pulmonary Disease (COPD) by its partner Topigen Pharmaceuticals Inc. TPI 1020 showed good overall safety and tolerability, although its activity profile was not significantly different from budesonide, a conventional corticosteroid commonly used in respiratory disorders. TPI 1020 is a new chemical entity licensed from NicOx for respiratory indications. The two co-primary objectives of the study were the safety and tolerability of inhaled TPI 1020 in COPD patients and the effect of TPI 1020 on sputum neutrophil counts compared to...
Source: Health Business Week (2009-01-09)
|
